BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med 2014;20:463-71. [PMID: 25022315 DOI: 10.1097/MCP.0000000000000091] [Cited by in Crossref: 41] [Cited by in F6Publishing: 12] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Hoyer N, Thomsen LH, Wille MMW, Wilcke T, Dirksen A, Pedersen JH, Saghir Z, Ashraf H, Shaker SB. Increased respiratory morbidity in individuals with interstitial lung abnormalities. BMC Pulm Med 2020;20:67. [PMID: 32188453 DOI: 10.1186/s12890-020-1107-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Liu H, Li Y, Zou Y, Zhang X, Shi X, Yin Z, Lin Y. Influence of miRNA-30a-5p on Pulmonary Fibrosis in Mice with Streptococcus pneumoniae Infection through Regulation of Autophagy by Beclin-1. Biomed Res Int 2021;2021:9963700. [PMID: 34604389 DOI: 10.1155/2021/9963700] [Reference Citation Analysis]
3 Ji X, Wu B, Fan J, Han R, Luo C, Wang T, Yang J, Han L, Zhu B, Wei D, Chen J, Ni C. The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis. Sci Rep 2015;5:14131. [PMID: 26370615 DOI: 10.1038/srep14131] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 8.3] [Reference Citation Analysis]
4 Mathai SK, Schwartz DA. Taking the "I" out of IPF. Eur Respir J 2015;45:1539-41. [PMID: 26028619 DOI: 10.1183/09031936.00052715] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Barratt SL, Davis R, Sharp C, Pauling JD. The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review. ERJ Open Res 2020;6:00027-2020. [PMID: 32832530 DOI: 10.1183/23120541.00027-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Mancuzo EV, Soares MR, Pereira CAC. Six-minute walk distance and survival time in patients with idiopathic pulmonary fibrosis in Brazil. J Bras Pneumol 2018;44:267-72. [PMID: 30328926 DOI: 10.1590/S1806-37562018000000049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mathai SK, Yang IV, Schwarz MI, Schwartz DA. Incorporating genetics into the identification and treatment of Idiopathic Pulmonary Fibrosis. BMC Med 2015;13:191. [PMID: 26400796 DOI: 10.1186/s12916-015-0434-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
8 Hagmeyer L, Herkenrath S, Anduleit N, Treml M, Randerath W. Cardiopulmonary Exercise Testing Allows Discrimination Between Idiopathic Non-specific Interstitial Pneumonia and Idiopathic Pulmonary Fibrosis in Mild to Moderate Stages of the Disease. Lung 2019;197:721-6. [PMID: 31676976 DOI: 10.1007/s00408-019-00282-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
9 Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2017;196:756-61. [PMID: 28471697 DOI: 10.1164/rccm.201701-0091OC] [Cited by in Crossref: 87] [Cited by in F6Publishing: 34] [Article Influence: 17.4] [Reference Citation Analysis]
10 Nawroth JC, Barrile R, Conegliano D, van Riet S, Hiemstra PS, Villenave R. Stem cell-based Lung-on-Chips: The best of both worlds? Adv Drug Deliv Rev 2019;140:12-32. [PMID: 30009883 DOI: 10.1016/j.addr.2018.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
11 Kropski JA, Blackwell TS. Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis. Annu Rev Med 2019;70:211-24. [PMID: 30691371 DOI: 10.1146/annurev-med-041317-102715] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
12 Morrow LE, Hilleman D, Malesker MA. Management of patients with fibrosing interstitial lung diseases. Am J Health Syst Pharm 2021:zxab375. [PMID: 34608488 DOI: 10.1093/ajhp/zxab375] [Reference Citation Analysis]
13 Conforti F, Davies ER, Calderwood CJ, Thatcher TH, Jones MG, Smart DE, Mahajan S, Alzetani A, Havelock T, Maher TM, Molyneaux PL, Thorley AJ, Tetley TD, Warner JA, Packham G, Ganesan A, Skipp PJ, Marshall BJ, Richeldi L, Sime PJ, O'Reilly KMA, Davies DE. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget 2017;8:48737-54. [PMID: 28467787 DOI: 10.18632/oncotarget.17114] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
14 Collins BF, Spiekerman CF, Shaw MA, Ho LA, Hayes J, Spada CA, Stamato CM, Raghu G. Idiopathic Interstitial Pneumonia Associated With Autoantibodies: A Large Case Series Followed Over 1 Year. Chest 2017;152:103-12. [PMID: 28300570 DOI: 10.1016/j.chest.2017.03.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]